Stephanie R Shepheard1, Vassilios Karnaros1, Beben Benyamin2, David W Schultz3, Megan Dubowsky1, Joanne Wuu4, Tim Chataway1, Andrea Malaspina5, Michael Benatar4, Mary-Louise Rogers1. 1. Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia. 2. Australian Centre for Precision Health and Allied Health and Human Performance Unit, University of South Australia, Adelaide, South Australia, Australia. 3. Neurology Department and MND Clinic, Flinders Medical Centre, Adelaide, South Australia, Australia. 4. Department of Neurology, Miller School of Medicine, University of Miami, Miami, Florida, USA. 5. Neuromuscular Department, Motor Neuron Disease Centre, UCL Queen Square Institute of Neurology, London, UK.
Abstract
BACKGROUND AND PURPOSE: The aim was to evaluate urinary neopterin, a marker of pro-inflammatory state, as a potential biomarker of disease prognosis and progression in amyotrophic lateral sclerosis (ALS); and to compare its utility to urinary neurotrophin receptor p75 extracellular domain (p75ECD ). METHODS: This was an observational study including 21 healthy controls and 46 people with ALS, 29 of whom were sampled longitudinally. Neopterin and p75ECD were measured using enzyme-linked immunoassays. Baseline and longitudinal changes in clinical measures, neopterin and urinary p75ECD were examined, and prognostic utility was explored by survival analysis. RESULTS: At baseline, urinary neopterin was higher in ALS compared to controls (181.7 ± 78.9 μmol/mol creatinine vs. 120.4 ± 60.8 μmol/mol creatinine, p = 0.002, Welch's t test) and correlated with the Revised ALS Functional Rating Scale (r = -0.36, p = 0.01). Combining previously published urinary p75ECD results from 22 ALS patients with a further 24 ALS patients, baseline urinary p75ECD was also higher compared to healthy controls (6.0 ± 2.7 vs. 3.2 ± 1.0 ng/mg creatinine, p < 0.0001) and correlated with the Revised ALS Functional Rating Scale (r = -0.36, p = 0.01). Urinary neopterin and p75ECD correlated with each other at baseline (r = 0.38, p = 0.009). In longitudinal analysis, urinary neopterin increased on average (±SE) by 6.8 ± 1.1 µmol/mol creatinine per month (p < 0.0001) and p75ECD by 0.19 ± 0.02 ng/mg creatinine per month (p < 0.0001) from diagnosis in 29 ALS patients. CONCLUSION: Urinary neopterin holds promise as marker of disease progression in ALS and is worthy of future evaluation for its potential to predict response to anti-inflammatory therapies.
BACKGROUND AND PURPOSE: The aim was to evaluate urinary neopterin, a marker of pro-inflammatory state, as a potential biomarker of disease prognosis and progression in amyotrophic lateral sclerosis (ALS); and to compare its utility to urinary neurotrophin receptor p75 extracellular domain (p75ECD ). METHODS: This was an observational study including 21 healthy controls and 46 people with ALS, 29 of whom were sampled longitudinally. Neopterin and p75ECD were measured using enzyme-linked immunoassays. Baseline and longitudinal changes in clinical measures, neopterin and urinary p75ECD were examined, and prognostic utility was explored by survival analysis. RESULTS: At baseline, urinary neopterin was higher in ALS compared to controls (181.7 ± 78.9 μmol/mol creatinine vs. 120.4 ± 60.8 μmol/mol creatinine, p = 0.002, Welch's t test) and correlated with the Revised ALS Functional Rating Scale (r = -0.36, p = 0.01). Combining previously published urinary p75ECD results from 22 ALS patients with a further 24 ALS patients, baseline urinary p75ECD was also higher compared to healthy controls (6.0 ± 2.7 vs. 3.2 ± 1.0 ng/mg creatinine, p < 0.0001) and correlated with the Revised ALS Functional Rating Scale (r = -0.36, p = 0.01). Urinary neopterin and p75ECD correlated with each other at baseline (r = 0.38, p = 0.009). In longitudinal analysis, urinary neopterin increased on average (±SE) by 6.8 ± 1.1 µmol/mol creatinine per month (p < 0.0001) and p75ECD by 0.19 ± 0.02 ng/mg creatinine per month (p < 0.0001) from diagnosis in 29 ALS patients. CONCLUSION: Urinary neopterin holds promise as marker of disease progression in ALS and is worthy of future evaluation for its potential to predict response to anti-inflammatory therapies.
Authors: Y Yoshida; F Une; Y Utatsu; M Nomoto; Y Furukawa; Y Maruyama; N Machigashira; T Matsuzaki; M Osame Journal: Intern Med Date: 1999-02 Impact factor: 1.271
Authors: Yunlan Du; Weihua Zhao; Jason R Thonhoff; Jinghong Wang; Shixiang Wen; Stanley H Appel Journal: Exp Neurol Date: 2020-02-24 Impact factor: 5.330
Authors: Harald Mischak; Walter Kolch; Michalis Aivaliotis; David Bouyssié; Magali Court; Hassan Dihazi; Gry H Dihazi; Julia Franke; Jérôme Garin; Anne Gonzalez de Peredo; Alexander Iphöfer; Lothar Jänsch; Chrystelle Lacroix; Manousos Makridakis; Christophe Masselon; Jochen Metzger; Bernard Monsarrat; Michal Mrug; Martin Norling; Jan Novak; Andreas Pich; Andrew Pitt; Erik Bongcam-Rudloff; Justyna Siwy; Hitoshi Suzuki; Visith Thongboonkerd; Li-Shun Wang; Jérôme Zoidakis; Petra Zürbig; Joost P Schanstra; Antonia Vlahou Journal: Proteomics Clin Appl Date: 2010-02-03 Impact factor: 3.494
Authors: Michael Benatar; Kevin Boylan; Andreas Jeromin; Seward B Rutkove; James Berry; Nazem Atassi; Lucie Bruijn Journal: Muscle Nerve Date: 2015-12-29 Impact factor: 3.217
Authors: Robert G Miller; Gilbert Block; Jonathan S Katz; Richard J Barohn; Vidhya Gopalakrishnan; Merit Cudkowicz; Jane R Zhang; Michael S McGrath; Elizabeth Ludington; Stan H Appel; Ari Azhir Journal: Neurol Neuroimmunol Neuroinflamm Date: 2015-04-09
Authors: Ozlem Yildiz; Johannes Schroth; Vittoria Lombardi; Valentina Pucino; Yoana Bobeva; Ping Kei Yip; Klaus Schmierer; Claudio Mauro; Timothy Tree; Sian Mari Henson; Andrea Malaspina Journal: Int J Mol Sci Date: 2022-03-21 Impact factor: 6.208